Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PERPHENAZINE

4 general benefit · 4 not a benefit

Other products in the same Health Canada class (N05A, N05AB) — coverage varies; not interchangeable

  • Fluphenazine (Moditen HCL): general benefit, Not a benefit
  • Prochlorperazine (Prochlorazine): general benefit, Not a benefit
  • Trifluoperazine (Trifluoperazine): general benefit, Not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Asenapine (Saphris): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Perphenazine · DIN 00335134 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Perphenazine · DIN 00335134 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2010-11-23 · brand PERPHENAZINE · ATC N05AB03 PERPHENAZINE · form Tablet · route Oral · ingredients PERPHENAZINE 2 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Perphenazine: Formulary list price $0.0683/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0683 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2368 · Verify on the e-Formulary ↗ (DIN 00335134)

Source record
DIN 00335134: Perphenazine Raw flags: sec3=Y Item: 281608057; group id 503; item number 1308; lccId None; manufacturer id AAP Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.0683; ministry $0.0683 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00335134 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2368
Interchangeable products
Trilafon · DIN 00028290 · not recorded
Shortage status: resolved shortage (ended 2022-08-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00335134
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Perphenazine · DIN 00335126 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Perphenazine · DIN 00335126 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2010-10-19 · brand PERPHENAZINE · ATC N05AB03 PERPHENAZINE · form Tablet · route Oral · ingredients PERPHENAZINE 4 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Perphenazine: Formulary list price $0.0826/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0826 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2367 · Verify on the e-Formulary ↗ (DIN 00335126)

Source record
DIN 00335126: Perphenazine Raw flags: sec3=Y Item: 281608056; group id 503; item number 1309; lccId None; manufacturer id AAP Source form: Tab; strength: 4mg Recorded listing: General benefit Source prices (unrounded): $0.0826; ministry $0.0826 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00335126 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2367
Interchangeable products
Trilafon · DIN 00028304 · not recorded
Shortage status: resolved shortage (ended 2025-10-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00335126
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Perphenazine · DIN 00335118 · 8mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Perphenazine · DIN 00335118 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2010-10-22 · brand PERPHENAZINE · ATC N05AB03 PERPHENAZINE · form Tablet · route Oral · ingredients PERPHENAZINE 8 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Perphenazine: Formulary list price $0.0908/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0908 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2366 · Verify on the e-Formulary ↗ (DIN 00335118)

Source record
DIN 00335118: Perphenazine Raw flags: sec3=Y Item: 281608055; group id 503; item number 1310; lccId None; manufacturer id AAP Source form: Tab; strength: 8mg Recorded listing: General benefit Source prices (unrounded): $0.0908; ministry $0.0908 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00335118 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2366
Interchangeable products
Trilafon · DIN 00028312 · not recorded
Shortage status: resolved shortage (ended 2024-10-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00335118
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Perphenazine · DIN 00335096 · 16mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Perphenazine · DIN 00335096 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2010-11-25 · brand PERPHENAZINE · ATC N05AB03 PERPHENAZINE · form Tablet · route Oral · ingredients PERPHENAZINE 16 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Perphenazine: Formulary list price $0.1389/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1389 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2365 · Verify on the e-Formulary ↗ (DIN 00335096)

Source record
DIN 00335096: Perphenazine Raw flags: sec3=Y Item: 281608097; group id 503; item number 1311; lccId None; manufacturer id AAP Source form: Tab; strength: 16mg Recorded listing: General benefit Source prices (unrounded): $0.1389; ministry $0.1389 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00335096 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2365
Interchangeable products
Trilafon · DIN 00028320 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00335096
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Trilafon · PIN 00028320 · 16mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Trilafon · DIN 00028320 Manufacturer: Schering Canada Inc.; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Trilafon: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00028320)

Source record
DIN 00028320: Trilafon Raw flags: notABenefit=Y, sec3=Y Item: 281608097; group id 503; item number 1311; lccId None; manufacturer id SCH Source form: Tab; strength: 16mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00028320 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Perphenazine · DIN 00335096 · $0.1389
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00028320
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Trilafon · DIN 00028290 · 2mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-11 — choose a marketed DIN from the same-category list.Discontinued 2000-07-11 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-11 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-07-11 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Trilafon · DIN 00028290 Manufacturer: Schering Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2000-07-11 · brand TRILAFON TAB 2MG · ATC N05AB03 PERPHENAZINE · form Tablet · route Oral · ingredients PERPHENAZINE 2 MG/TAB · company Schering-plough canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Trilafon: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=375 · Verify on the e-Formulary ↗ (DIN 00028290)

Source record
DIN 00028290: Trilafon Raw flags: notABenefit=Y, sec3=Y Item: 281608057; group id 503; item number 1308; lccId None; manufacturer id SCH Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00028290 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=375
Interchangeable products
Perphenazine · DIN 00335134 · $0.0683
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00028290
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2000-07-11 — choose a marketed DIN from the same-category list.

Trilafon · DIN 00028304 · 4mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-11-17 — choose a marketed DIN from the same-category list.Discontinued 1998-11-17 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-11-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1998-11-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Trilafon · DIN 00028304 Manufacturer: Schering Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 1998-11-17 · brand TRILAFON TAB 4MG · ATC N05AB03 PERPHENAZINE · form Tablet · route Oral · ingredients PERPHENAZINE 4 MG/TAB · company Schering-plough canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Trilafon: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=376 · Verify on the e-Formulary ↗ (DIN 00028304)

Source record
DIN 00028304: Trilafon Raw flags: notABenefit=Y, sec3=Y Item: 281608056; group id 503; item number 1309; lccId None; manufacturer id SCH Source form: Tab; strength: 4mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00028304 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=376
Interchangeable products
Perphenazine · DIN 00335126 · $0.0826
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00028304
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1998-11-17 — choose a marketed DIN from the same-category list.

Trilafon · DIN 00028312 · 8mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.Discontinued 1996-09-10 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Trilafon · DIN 00028312 Manufacturer: Schering Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 1996-09-10 · brand TRILAFON TAB 8MG · ATC N05AB03 PERPHENAZINE · form Tablet · route Oral · ingredients PERPHENAZINE 8 MG/TAB · company Schering-plough canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Trilafon: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=377 · Verify on the e-Formulary ↗ (DIN 00028312)

Source record
DIN 00028312: Trilafon Raw flags: notABenefit=Y, sec3=Y Item: 281608055; group id 503; item number 1310; lccId None; manufacturer id SCH Source form: Tab; strength: 8mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00028312 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=377
Interchangeable products
Perphenazine · DIN 00335118 · $0.0908
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00028312
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

PROCHLORPERAZINE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 5mg, 10mg · Tab

TRIFLUOPERAZINE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 1mg, 2mg, 5mg, 10mg · Tab

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: manifestations of psychotic disorders
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. FLUPHENAZINE HCL · Listed, not a benefit (3), General benefit (3) 1 INDICATIONS FLUPHENAZINE (fluphenazine hydrochloride) is indicated for: • Management of manifestations of psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00069653.PDF; date DEC 31, 1977; DIN 00405345; fetched 2026-09-10 Product monograph PROCHLORPERAZINE · General benefit (2), Listed, not a benefit (2) Indications PROCHLORAZINE (Prochlorperazine Maleate Tablets) is indicated for: • the management of manifestations of psychotic disorders such as agitation, confusion, delusion, tension and anxiety. PM: https://pdf.hres.ca/dpd_pm/00082835.PDF; date 2025-12-15; DIN 00886432; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications PERPHENAZINE (perphenazine tablets) is indicated for: • Management of manifestations of psychotic disorders. • Controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone. PERPHENAZINE has not been shown effective for the management of behavioral complications in patients with intellectual developmental disorder. 1.1. Pediatrics Pediatrics (<13 years of age): No data are available to Health Canada regarding use in children under 13 years of age; therefore, Health Canada has not authorized an indication for pediatric use in children under 13 years of age. See 7.1.3 Pediatrics and 4.1 Dosage Considerations. 1.2. Geriatrics Geriatrics (>55 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 3 Serious Warnings and Precautions Box and 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00084763.PDF PM date: May 15, 2026 Source product: PERPHENAZINE; DIN 00335096; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Trilafon: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026